← Issue №6/ week of Aug 9, 2026/Endoscopy

EUS-guided biopsy using 19-gauge Franseen needle versus percutaneous ultrasound-guided biopsy using 18-gauge full-core cutting needle for parenchymal liver disease: A randomized controlled, non-inferiority trial.

From GI Signals issue №6: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Endoscopy rct · n=90 · Aug 11, 2026 · GIE · IF 8.0

EUS-guided biopsy using 19-gauge Franseen needle versus percutaneous ultrasound-guided biopsy using 18-gauge full-core cutting needle for parenchymal liver disease: A randomized controlled, non-inferiority trial.

New evidenceEUS
What it foundEUS-guided liver biopsy with 19-gauge Franseen needle achieved specimen adequacy (length ≥15 mm and ≥8 complete portal tracts) in 97.8% versus 64.4% with percutaneous 18-gauge biopsy; median specimen lengths were 6.9 cm versus 2.0 cm and median complete portal tracts 42 versus 9.
ContextPreviously there was limited comparative data between endoscopic and percutaneous liver biopsy approaches. This RCT demonstrates EUS-LB's substantial superiority for tissue adequacy, a critical requirement for accurate histologic diagnosis of parenchymal liver disease.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Johri I … Daniel J · Gastrointestinal Endoscopy · IF 8.0 · PubMed ↗Permalink
← Read the whole of issue №6 Every paper GI Signals surfaces gets a page like this one. All issues